NASDAQ:URGN

Urogen Pharma Stock Insider Trading

Healthcare > Biotechnology

Buy URGN

*Your capital is at risk

$38.24

-2.85 (-6.94%)

At Close: Jul 31, 2026

UroGen Pharma Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -3.25. In total, the insiders bought 828.13K and sold 101.93K URGN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-3.25
● Buy	828.13K shares
● Sell	101.93K shares
79% Buy Activity Strong Negative Correlation
Sell Signal Medium Confidence Jul 09, 2026 Analysis Breakdown: Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 31, 2026 Buy	Ordinary Shares M-Exempt	Smith Jason Drew General Counsel	Officer	3 333 Value: $127.5K
Jan 31, 2026 Buy	Ordinary Shares M-Exempt	Smith Jason Drew General Counsel	Officer	5 500 Value: $210.3K
Jan 31, 2026 Buy	Ordinary Shares M-Exempt	Smith Jason Drew General Counsel	Officer	6 667 Value: $254.9K
Jan 31, 2026 Buy	Restricted Stock Units A-Award	Smith Jason Drew General Counsel	Officer	32 609 Value: $1.25M
Jan 31, 2026 Buy	Restricted Stock Units M-Exempt	Smith Jason Drew General Counsel	Officer	3 333 Value: $127.5K
Jan 31, 2026 Buy	Restricted Stock Units M-Exempt	Smith Jason Drew General Counsel	Officer	5 500 Value: $210.3K
Jan 31, 2026 Buy	Restricted Stock Units M-Exempt	Smith Jason Drew General Counsel	Officer	6 667 Value: $254.9K
Jan 31, 2026 Buy	Ordinary Shares M-Exempt	Schoenberg Mark Chief Medical Officer	Officer	3 333 Value: $127.5K
Jan 31, 2026 Buy	Ordinary Shares M-Exempt	Schoenberg Mark Chief Medical Officer	Officer	6 666 Value: $254.9K
Jan 31, 2026 Buy	Ordinary Shares M-Exempt	Schoenberg Mark Chief Medical Officer	Officer	3 334 Value: $127.5K
Jan 31, 2026 Buy	Restricted Stock Units A-Award	Schoenberg Mark Chief Medical Officer	Officer	20 000 Value: $764.8K
Jan 31, 2026 Buy	Restricted Stock Units M-Exempt	Schoenberg Mark Chief Medical Officer	Officer	6 666 Value: $254.9K
Jan 31, 2026 Buy	Restricted Stock Units M-Exempt	Schoenberg Mark Chief Medical Officer	Officer	3 333 Value: $127.5K
Jan 31, 2026 Buy	Restricted Stock Units M-Exempt	Schoenberg Mark Chief Medical Officer	Officer	3 334 Value: $127.5K
Jan 31, 2026 Buy	Restricted Stock Units A-Award	Degnan Chris Chief Financial Officer	C-Suite Officer	32 609 Value: $1.25M
Nov 26, 2025 Buy	ordinary shares M-Exempt	Wildman Daniel George Director	Director	2 000 Value: $58.8K
Nov 26, 2025 Buy	Restricted Stock Unit M-Exempt	Wildman Daniel George Director	Director	2 000 Value: $58.8K
Nov 26, 2025 Buy	ordinary shares M-Exempt	Wen Leana Director	Director	2 000 Value: $58.8K
Nov 26, 2025 Buy	Restricted Stock Unit M-Exempt	Wen Leana Director	Director	2 000 Value: $58.8K
Nov 26, 2025 Buy	ordinary shares M-Exempt	Robinson James A. Jr. Director	Director	2 000 Value: $58.8K
Nov 26, 2025 Buy	Restricted Stock Unit M-Exempt	Robinson James A. Jr. Director	Director	2 000 Value: $58.8K
Nov 26, 2025 Buy	ordinary shares M-Exempt	Butitta Cynthia M Director	Director	2 000 Value: $58.8K
Nov 26, 2025 Buy	Restricted Stock Unit M-Exempt	Butitta Cynthia M Director	Director	2 000 Value: $58.8K
Nov 26, 2025 Buy	ordinary shares M-Exempt	Holden Stuart Director	Director	2 000 Value: $58.8K
Nov 26, 2025 Buy	Restricted Stock Unit M-Exempt	Holden Stuart Director	Director	2 000 Value: $58.8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT UROGEN PHARMA LTD

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms...

Read Full Profile Here